Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

First Affiliated Hospital of Wenzhou Medical University · 2026
ClinicalTrials.gov · Datasets · License: Public Domain · 2026
Open Source ↗
carcinoma
urinary bladder neoplasms, carcinoma, transitional cell, carcinoma in situ of bladder, non-muscle-invasive bladder cancer, nmibc, high-risk nmibc, bcg-unresponsive, bcg-intolerant, bcg failure, carcinoma in situ (cis), intravesical therapy, ta
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗
Record · ID 833329
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.